447 related articles for article (PubMed ID: 23537813)
1. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.
Tanaka K; Essick EE; Doros G; Tanriverdi K; Connors LH; Seldin DC; Sam F
J Am Heart Assoc; 2013 Mar; 2(2):e005868. PubMed ID: 23537813
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
[TBL] [Abstract][Full Text] [Related]
3. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.
Cappelli F; Baldasseroni S; Bergesio F; Perlini S; Salinaro F; Padeletti L; Attanà P; Paoletti Perini A; Moggi Pignone A; Grifoni E; Fabbri A; Marchionni N; Gensini GF; Perfetto F
Clin Cardiol; 2015 Feb; 38(2):69-75. PubMed ID: 25645201
[TBL] [Abstract][Full Text] [Related]
4. Clinical and echocardiographic characteristics for differentiating between transthyretin-related and light-chain cardiac amyloidoses.
Mori M; An Y; Katayama O; Kitagawa T; Sasaki Y; Onaka T; Yonezawa A; Murata K; Yokota T; Ando K; Imada K
Ann Hematol; 2015 Nov; 94(11):1885-90. PubMed ID: 26251157
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
6. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
8. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis?
Suhr OB; Anan I; Backman C; Karlsson A; Lindqvist P; Mörner S; Waldenström A
J Intern Med; 2008 Mar; 263(3):294-301. PubMed ID: 18069997
[TBL] [Abstract][Full Text] [Related]
9. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
Lorenzl S; Buerger K; Hampel H; Beal MF
Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
[TBL] [Abstract][Full Text] [Related]
10. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs).
Bonnema DD; Webb CS; Pennington WR; Stroud RE; Leonardi AE; Clark LL; McClure CD; Finklea L; Spinale FG; Zile MR
J Card Fail; 2007 Sep; 13(7):530-40. PubMed ID: 17826643
[TBL] [Abstract][Full Text] [Related]
11. Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome.
Gomes VA; Vieira CS; Jacob-Ferreira AL; Belo VA; Soares GM; Fernandes JB; Ferriani RA; Tanus-Santos JE
Mol Cell Biochem; 2011 Jul; 353(1-2):251-7. PubMed ID: 21437624
[TBL] [Abstract][Full Text] [Related]
12. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
14. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
15. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
17. MMPs/TIMPs imbalances in the peripheral blood and cerebrospinal fluid are associated with the pathogenesis of HIV-1-associated neurocognitive disorders.
Xing Y; Shepherd N; Lan J; Li W; Rane S; Gupta SK; Zhang S; Dong J; Yu Q
Brain Behav Immun; 2017 Oct; 65():161-172. PubMed ID: 28487203
[TBL] [Abstract][Full Text] [Related]
18. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
19. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.
Giannelli G; Erriquez R; Fransvea E; Daniele A; Trerotoli P; Schittulli F; Grano M; Quaranta M; Antonaci S
Int J Cancer; 2004 May; 109(5):782-5. PubMed ID: 14999790
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
